Magazine Article | April 6, 2018

Companies To Watch: CytoDyn

Source: Life Science Leader

By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein

Phase 3 monoclonal to block HIV from infecting T cells, and earlier hopefuls.

CytoDyn is in late-stage development of its lead drug, PRO 140 (leronlimab) for treating HIV infection as a unique CCR5-blocking monoclonal agent in the new class of “viral-entry” inhibitors. PRO 140 has just completed and announced positive data from a Phase 2b/3 clinical trial in combination with existing anti-HIV therapies and will produce data from its Phase 3 monotherapy trial later this year. It also is in a Phase 2 trial in prevention of graft-versus-host disease (GVHD). The company has other products and indications in development at earlier stages in its pipeline.